Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 17, Issue 1-2, 2016, Pages 85-92

  Grieve, Stuart M ^a,b   Menon, Parvathi ^c,d   Korgaonkar, Mayuresh S ^a,b,c   Gomes, Lavier ^c   Foster, Sheryl ^c   Kiernan, Matthew C ^b   Vucic, Steve ^a,b,c,d  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d University of Sydney   (Australia)

Author keywords

ALS; Cortical thickness; SICI

Indexed keywords

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE MARKER; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MOTONEURON; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; UPPER MOTOR NEURON; ARM; BRAIN MAPPING; FEASIBILITY STUDY; MIDDLE AGED; MOTOR CORTEX; MUSCULAR DISEASES; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

BIOLOGICAL MARKER;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARM; BIOMARKERS; BRAIN MAPPING; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR CORTEX; MUSCULAR DISEASES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84955706248     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2015.1074707     Document Type: Article

References (43)

1. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011; 377: 942-55.
2. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2000; 1: 293-9.
3. Turner MR, Kiernan MC, Leigh PN, Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 2009; 8: 94-109.
4. de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008; 119: 497-503.
5. Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012; 69: 1410-16.
6. Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2012; 83: 659-62.
7. Higashihara M, Sonoo M, Imafuku I, Fukutake T, Kamakura K, Inoue K, et al. Fasciculation potentials in amyotrophic lateral sclerosis and the diagnostic yield of the Awaji algorithm. Muscle Nerve. 2012; 45: 175-82.
8. Vucic S, Rothstein JD, Kiernan MC. Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends Neurosci. 2014; 37: 433-42.
9. Turner MR, Grosskreutz J, Kassubek J, Abrahams S, Agosta F, Benatar M, et al. Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurol. 2011; 10: 400-3.
10. Grosskreutz J, Kaufmann J, Fradrich J, Dengler R, Heinze H-J, Peschel T. Widespread sensorimotor and frontal cortical atrophy in amyotrophic lateral sclerosis. BMC Neurol. 2006; 6: 17.
11. Minnerop M, Specht K, Ruhlmann J, Grothe C, Wüllner U, Klockgether T. In vivo voxel-based relaxometry in amyotrophic lateral sclerosis. J Neurol. 2009; 256: 28-34.
12. Senda J, Kato S, Kaga T, Ito M, Atsuta N, Nakamura T, et al. Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study. Amyotroph Lateral Scler. 2011; 12: 59-69.
13. Agosta F, Pagani E, Petrolini M, Caputo D, Perini M, Prelle A, et al. Assessment of White Matter Tract Damage in Patients with Amyotrophic Lateral Sclerosis: A Diffusion Tensor MR Imaging Tractography Study. AJNR Am J Neuroradiol. 2010; 31: 1457-61.
14. Foerster BR, Dwamena BA, Petrou M, Carlos RC, Callaghan BC, Churchill CL, et al. Diagnostic Accuracy of Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis: A Systematic Review and Individual Patient Data Meta-Analysis. Acad Radiol. 2013; 20: 1099-106.
15. Walhout R, Westeneng H-J, Verstraete E, Hendrikse J, Veldink JH, van den Heuvel MP, et al. Cortical thickness in ALS: towards a marker for upper motor neuron involvement. J Neurol Neurosurg Psychiatry. 2015; 86: 288-94.
16. Verstraete E, Veldink JH, Hendrikse J, Schelhaas HJ, van den Heuvel MP, van den Berg LH. Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012; 83: 383-8.
17. Mezzapesa DM, D'Errico E, Tortelli R, Distaso E, Cortese R, Tursi M, et al. Cortical thinning and clinical heterogeneity in amyotrophic lateral sclerosis. PLoS One. 2013; 8: e80748.
18. Vucic S, Ziemann U, Eisen A, Hallett M, Kiernan MC. Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. J Neurol Neurosurg Psychiatry. 2013; 84: 1161-70.
19. Vucic S, Howells J, Trevillion L, Kiernan MC. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve. 2006; 33: 477-86.
20. Geevasinga N, Menon P, Yiannikas C, Kiernan MC, Vucic S. Diagnostic utility of cortical excitability studies in amyotrophic lateral sclerosis. Eur J Neurol. 2014; 21: 1451-7.
21. Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011; 122: 1860-6.
22. Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008; 131: 1540-50.
23. Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiol. 2014;doi: 10.1016.
24. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21.
25. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006; 66: 265-7.
26. OBrien MD. Aid to the examination of the peripheral nervous system. London: W.B.Saunders; 2004. pp 1-3.
27. Turner M, Cagnin A, Turkheimer F, Miller C, Shaw C, Brooks D, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15: 601-9.
28. Grieve SM, Korgaonkar MS, Koslow SH, Gordon E, Williams LM. Widespread reductions in grey matter volume in depression. Neuroimage Clin. 2013; 3: 332-9.
29. Korgaonkar MS, Grieve SM, Koslow SH, Gabrieli JDE, Gordon E, Williams LM. Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging. Hum Brain Mapp. 2011; 32: 2161-71.
30. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc Nat Acad Sci U S A. 2000; 97: 11050-5.
31. Grieve SM, Korgaonkar MS, Koslow SH, Gordon E, Williams LM. Widespread reductions in grey matter volume in depression. NeuroImage: Clin. 2013; 3: 332-9.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995; 57: 289-300.
33. Rossini PM, Berardelli A, Deuschl G, Hallett M, Maertens de Noordhout AM, Paulus W, et al. Applications of magnetic cortical stimulation. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52: 171-85.
34. Ziemann U. TMS and drugs. Clin Neurophysiol. 2004; 115: 1717-29.
35. Paganoni S, Macklin EA, Lee A, Murphy A, Chang J, Zipf A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler. 2014; 15: 453-6.
36. Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain. 2006; 129: 2436-46.
37. Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathologica. 1993; 86: 55-64.
38. Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology. 2003; 60: 1094-7.
39. Elamin M, Bede P, Byrne S, Jordan N, Gallagher L, Wynne B, et al. Cognitive changes predict functional decline in ALS: a population based longitudinal study. Neurology. 2013; 80: 1590-7.
40. Eisen A, Kim S, Pant B. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron? Muscle Nerve. 1992; 15: 219-24.
41. Renton Alan E, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A Hexanucleotide Repeat Expansion in C9orf72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011; 72: 257-68.
42. DeJesus-Hernandez M, Mackenzie Ian R, Boeve Bradley F, Boxer Adam L, Baker M, Rutherford Nicola J, et al. Expanded GGGGCC Hexanucleotide Repeat in Non-coding Region of C9orf72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011; 72: 245-56.
43. Lillo P, Hodges JR. Frontotemporal dementia and motor neuron disease: overlapping clinic-pathological disorders. J Clin Neurosci. 2009; 16: 1131-5.